This webinar will address software that is:
Process and/or In Production and Test Equipment and
The Quality System/CGMPs
A manufacturer is responsible to identify these requirements and implement them into an effective software V&V process.
Why You Should Attend: Software has become pervasive in medical devices themselves, and in the controlling, running and monitoring of medical product processes, whether they be in the pharmaceutical, medical device, biologics or dietary supplements industries. A quick review of Internet forums will show much confusion about the subject. Software is being developed for medical imaging, and even thought control of computers. It is increasingly being used for e-records and e-signatures.
The U.S. FDA rightly recognizes that virtually all software quality problems occur in the design, testing and validation phases, since replication of software is relatively defect-free. Regulatory auditors are more comfortable with delving into software isssues. Effective and real world software V&V is even more important in today’s resource constrained industrial environment. This discussion will focus on a preferred U.S. FDA documentation 'model' in various applications, including ERP, in-device, as-device, process/equipment control, and cGMP data / 21 CFR Part 11 (and EU Annex 11) applications.
Areas Covered in the Session:
Verification or Validation-FDA Expectations
The Project V&V Plan
An FDA-accepted Documentation 'Model'
Product and Process/Test Facilities/Equipment Software V&V
When and How to Use DQ, IQ, OQ, PQ (or their equivalents)
The FDA's 11 Key V&V Documentation Elements
'White Box' and 'Black Box' Validations
IEC 62304, GAMP/Other Considerations
John E. Lincoln,